Lidocaine HCI Injection, USP, 2%, by Hospira Recalled: AttorneyOne Monitors and Keeps Consumers Informed

Share Article

On July 30, the FDA published that one lot of Lidocaine HCI Injection, USP, 2%, by Hospira is recalled due to visible particulates. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

Lidocaine HCI Injection, by Hospira, Recalled

Lidocaine HCI Injection, by Hospira, Recalled

Anyone with existing inventory should immediately stop use and quarantine any affected product.

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Lidocaine HCI Injection.

The US FDA published on July 30, that one lot of Lidocaine HCI Injection, USP, 2%, 20 mg per mL, 5 mL single-Dose Vial, Preservative-Free, by Hospira is recalled due to visible particulates.

The reason for the recall is based on a customer report of visible particles in the solution as well as particulate embedded in the molded glass container identified as iron oxide.

If the particulate is injected, it can block administration and cause local inflammation, immune response to the particulate, or mechanical disruption of tissue. Moreover, in rare cases it can cause tissue damage if exposed to strong magnetic fields.

The affected lot is NDC 0409-2066-05; Lot 25-550-DD, Expiry 1JAN2015.

Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “we are determined to keep an eye on FDA announcements concerning Lidocaine HCI Injection and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”

As the FDA recommends “Anyone with existing inventory should immediately stop use and quarantine any affected product.” And the Agency adds “In addition, customers should inform potential users of this product in their organizations of this notification.”

AttorneyOne.com has further information on Lidocaine HCI Injection at the website including latest major drug, medical products, and food law news.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/08/prweb12060150.htm.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Sean Burke
Attorney One
+1 877-230-7343
Email >
@Attorney_One
Follow >
Visit website